Cargando…
Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma
Immune checkpoint inhibitors have been approved as second-line therapy for patients with advanced urothelial carcinoma (UC). However, which patients will obtain clinical benefit remains to be determined. To identify predictive biomarkers for the pembrolizumab (PEM) response early during treatment, t...
Autores principales: | Teshima, Taro, Kobayashi, Yukari, Kawai, Taketo, Kushihara, Yoshihiro, Nagaoka, Koji, Miyakawa, Jimpei, Akiyama, Yoshiyuki, Yamada, Yuta, Sato, Yusuke, Yamada, Daisuke, Tanaka, Nobuyuki, Tsunoda, Tatsuhiko, Kume, Haruki, Kakimi, Kazuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219027/ https://www.ncbi.nlm.nih.gov/pubmed/35765279 http://dx.doi.org/10.3892/ol.2022.13384 |
Ejemplares similares
-
A case of miliary tuberculosis following transurethral surgery and prostate biopsy after intravesical Bacillus Calmette–Guerin immunotherapy
por: Kurokawa, Yoshiaki, et al.
Publicado: (2021) -
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022) -
The prognostic value of PD‐L1 expression in upper tract urothelial carcinoma varies according to platelet count
por: Miyama, Yu, et al.
Publicado: (2018) -
The association between the parameters of uroflowmetry and lower urinary tract symptoms in prostate cancer patients after robot-assisted radical prostatectomy
por: Takeshima, Yuta, et al.
Publicado: (2022) -
Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy
por: Takeshima, Yuta, et al.
Publicado: (2021)